Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
BURLINGAME, Calif., Jan. 04, 2018 -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with NGM Biopharmaceuticals, Inc. The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.
“Ablexis is pleased to add NGM to the list of leading biopharmaceutical companies that are using the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse is already being used by the majority of the world’s top 15 pharmaceutical companies, more than any other next generation antibody discovery platform. Ablexis’ greater licensing flexibility is supporting our continuing mission to expand licensing of the AlivaMab Mouse for the rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses. More information can be found by visiting the Company’s website at www.ablexis.com.
Ablexis Corporate Contact:
Ablexis, LLC
Larry Green, (415) 967-1220
[email protected]
Ablexis Media Contact:
Red House Communications
Denise Powell, (510) 703-9491
[email protected]
